Welcome to our dedicated page for Lipocine SEC filings (Ticker: LPCN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a biotech filing packed with pharmacokinetic tables, trial endpoints, and FDA correspondence can drain an entire afternoon. Lipocine’s disclosures are doubly challenging because each 10-K details evolving clinical data for TLANDO and oral brexanolone, while every 8-K flags material events like Phase 2 topline results. If you have ever wondered, “How do I locate Lipocine insider trading Form 4 transactions before the next catalyst?” this page turns that frustration into clarity.
Stock Titan’s AI-powered analysis breaks down every Lipocine SEC filing—10-Qs, 10-Ks, S-1s, and real-time Form 4s—into concise summaries, risk matrices, and searchable highlights. You’ll see Lipocine quarterly earnings report 10-Q filing metrics side-by-side with liquidity runway charts, receive Form 4 insider transactions real-time alerts, and get plain-English answers to questions like “Why did Lipocine file an 8-K on trial enrollment?” or “What does the latest proxy statement executive compensation reveal?” No more scrolling through hundreds of pages; understanding Lipocine SEC documents with AI takes minutes.
Whether you’re tracking Lipocine executive stock transactions Form 4, looking for Lipocine earnings report filing analysis before modeling cash burn, or need a Lipocine annual report 10-K simplified view of pipeline milestones, you’ll find everything here. Our coverage refreshes the moment an EDGAR stamp appears, so Lipocine 8-K material events explained updates land in your dashboard instantly. Use the insights to monitor FDA timelines, compare quarter-over-quarter R&D spend, or spot insider sentiment shifts—practical intelligence that helps you act, not just read.
On 9 July 2025 Lipocine Inc. (NASDAQ: LPCN) filed a Form 8-K under Item 8.01 – Other Events. The sole disclosure is that the company hosted a virtual key-opinion-leader (KOL) event focused on LPCN 1154 (BRLIZIO™) as a potential treatment for postpartum depression. A webcast link and slide deck are available on the corporate website, and the materials have been furnished as Exhibit 99.1.
Under Item 9.01 the filing lists Exhibit 104 (Inline XBRL cover page). No financial metrics, clinical trial results, or transactional details accompany the notice. The document is signed by President & CEO Mahesh V. Patel.
This 8-K signals continued development and external engagement around LPCN 1154 but provides no new quantitative data likely to affect near-term valuation.
Lipocine Inc. (NASDAQ: LPCN) filed a Form 8-K dated July 2, 2025. Under Item 8.01 – Other Events, the company states that it has updated its corporate presentation, which it uses for discussions with investors and analysts. The revised deck is furnished as Exhibit 99.1 and is now publicly available.
No financial results, transactions, guidance changes or operational updates are included in this report. The filing is strictly informational, providing investors with access to the latest strategic and scientific materials that management will reference in upcoming meetings.
Lipocine (NASDAQ:LPCN) filed an 8-K announcing that the first patient has been dosed in its Phase 3 clinical trial of LPCN 1154 for postpartum depression. The disclosure, furnished under Item 8.01 with the press release attached as Exhibit 99.1, marks the transition of LPCN 1154 into late-stage development—an essential step toward potential NDA submission and commercialization. No changes to financial guidance, funding, or corporate strategy were reported, and Items 2.02, 5.02 or other sections were not included. While the filing contains no revenue figures, the milestone may accelerate future catalysts such as data read-outs, regulatory meetings and partnership discussions that could materially influence valuation.
Biofrontera Inc. (Nasdaq: BFRI) disclosed the results of its 12 June 2025 Annual Meeting of Stockholders via Form 8-K, Item 5.07. A quorum representing 6,338,347 votes was present. All four proposals were approved.
- Director election: Heikki Lanckriet was elected Class I director through 2028, receiving 4,565,450 votes for (≈93.3% support) versus 329,105 withheld and 1,443,792 broker non-votes.
- Authorized share increase: Stockholders approved an amendment to double authorized common shares from 35 million to 70 million (5,499,898 for; 837,939 against; 510 abstentions). This grants management wider capital-raising flexibility but could enable future dilution.
- Adjournment contingency: A precautionary motion to adjourn the meeting if necessary passed with 5,716,131 for versus 617,734 against.
- Auditor ratification: CBIZ CPAs P.C. was re-appointed for fiscal 2025 with 6,144,222 votes for (≈96.9% support).
The voting outcomes signal broad shareholder alignment with the board’s agenda, particularly on governance matters and capital structure flexibility. No financial performance metrics or transaction disclosures were included in this filing.
FAQ
What is the current stock price of Lipocine (LPCN)?
What is the market cap of Lipocine (LPCN)?
What is Lipocine Inc.'s core business?
What therapeutic areas does Lipocine target?
How does Lipocine's technology platform work?
What are some key products in Lipocine's pipeline?
How does Lipocine differentiate itself in the pharmaceutical industry?
What is the significance of Lipocine’s extensive R&D efforts?
How does Lipocine ensure quality and regulatory compliance?
What role do strategic partnerships play for Lipocine?
